Introduction
New medications are needed for people with mental disorders, and placebo-controlled randomized controlled trials (RCTs) are still the most common method to evaluate new medications. However, the use of a placebo in medicine, particularly in mental health disorders, remains a controversial topic. A 1997 position paper from the Canadian Psychiatric Association (CPA) summarized the arguments for and against the use of placebos, and concluded that placebo use was ethically and scientifically justified under certain conditions. 1 With the ongoing debate 2, 3 regarding the ethical, scientific, and clinical dilemmas associated with placebo use in clinical trials, and the recent revision of the Declaration of Helsinki code of ethics, 4 we now provide an update to the 1997 CPA position paper. We first briefly summarize the ethical aspects of placebo use, the positions of major funding and regulatory agencies, and the scientific and clinical issues in establishing efficacy and safety of new treatments. Then, we provide guidance and give clinical examples of ethical and scientific placebo use.
of clinical equipoise. 5 Clinical equipoise refers to a "genuine uncertainty on the part of the expert medical community about the comparative therapeutic merits of each arm of a clinical trial." 6 A placebo is therefore acceptable only when there is no established, evidencebased treatment for a condition, according to the relevant professional community. However, when an established treatment exists, an experimental treatment should be compared to the established treatment to minimize harm to research participants.
The Declaration of Helsinki, the code of ethics developed by the World Medical Association, was recently revised from its last clarification in 2002. The 2013 revision recommends that "the benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best proven intervention(s)." 4 The use of a less effective intervention is allowed in exceptional situations "where no proven intervention exists" or "where for compelling and scientifically sound methodological reasons, the use of any intervention less effective than the best proven one, the use of placebo, or no intervention, is necessary to determine the efficacy or safety of an intervention." 4 A precondition for both scenarios is that the patient will not be subject to additional risks of serious or irreversible harm as a result of not receiving the best-proven intervention.
Stance of Funding and Regulatory Agencies
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and pharmaceutical industry to determine the scientific and technical aspects of drug registration. ICH guidance emphasizes the importance of sound research methods, including randomization, blinding, and various control conditions (including placebo controls), to establish the efficacy and safety of new medications before they are approved for marketing. (Table 1) .
Scientific and Clinical Issues
Any new treatment must demonstrate efficacy (i.e., how a treatment performs under controlled conditions) and safety before it is approved for clinical use. Currently, comparing a new medication (or other type of treatment) to placebo (or sham treatment) using an RCT design is the most common and rigorous method for establishing efficacy and safety. Studies with noninferiority designs, 13 in which a new medication is compared only to an active, established treatment, generally require much larger sample sizes and are not as definitive for safety and tolerability as similar placebo-controlled studies. 14, 15 However, a placebo is not simply an inert substance. The patient assigned to placebo also benefits from nonspecific therapeutic effects of a clinical trial, including education, regular visits, psychosocial interactions with study staff, among other benefits. Thus, it is not surprising that placebo response is high in psychiatric and other chronic conditions where symptoms may fluctuate, and outcomes are based on patient interview or self-report.
High rates of placebo response are commonly found among patients with mental disorders. For example, antidepressant and antipsychotic trials in major depressive disorder (MDD) and schizophrenia have shown mean placebo response rates (ranges) of 31% (13% to 52%) and 25% (0% to 41%), respectively. [16] [17] [18] Hence, placebo response varies widely among studies. In addition, over the past 3 decades, antidepressant-placebo differences have declined markedly, 19 with similar findings reported from trials of antipsychotics for patients with schizophrenia. 20, 21 Because of the high placebo response, even "established" treatments may not demonstrate efficacy against a placebo. In a review of data from 45 studies submitted to the European regulatory authorities, 38% of antidepressant trials and 16% of antipsychotic trials were recorded as failed; i.e., when both the investigational and "established" reference medication did not separate from placebo. 22 Similarly, in an analysis of clinical trials of approved antidepressants submitted to the US Food and Drug Administration, only 53% of 81 trials found the active drug superior to the placebo. 23 Placebo response was even higher than "treatment as usual" conditions in MDD. 16 The presence or absence of a placebo in clinical trials may also influence both the response and dropout rates of active medications. For example, the degree of improvement with antipsychotics in active-controlled schizophrenia trials was nearly double that seen with the same drugs and dosages in placebo-controlled studies. 24 In studies of MDD, the response to an active antidepressant increases when there is less expectation to receive a placebo: response rates for active antidepressants are significantly higher in studies comparing 2 or more active medications without a placebo arm (65.4%) than in similar studies with a placebo (57.7%), and are lowest in studies comparing only one active medication with a placebo (51.7%). 25 Similarly, the dropout rates for active medications are higher in placebo-controlled antipsychotic trials than in trials with only active medication comparisons. 26 Because of these findings, noninferiority, active-control study designs may sometimes not be as valid as placebocontrolled designs in examining efficacy and safety.
The placebo-informed efficacy evidence also may not generalize to subgroups of patients with a particular diagnosis. Placebo-controlled trials of psychotropics are typically conducted in a narrow patient population with many exclusion criteria; but the findings are often generalized to other populations in "real life" clinical practice, such as different age groups or patients with comorbidities. Subsequent studies in patient subgroups may not support efficacy or may raise concerns about safety. For example, placebo-controlled studies of antidepressants for MDD in children and adolescents have smaller effect sizes and increased risk of suicidality when compared with similar studies in adults. 27 Hence, it may be scientifically and clinically important to establish efficacy using a placebo in subgroups of patients based on age, comorbidity, ethnicity, previous treatment nonresponse, and other characteristics.
Discussion
The ethical dilemma we face is that enrolment of patients in a clinical trial may hinder our fiduciary responsibility by potentially exposing them to ineffective treatments, both the experimental drug and placebo, thus delaying their active treatment. On the other hand, without properly controlled clinical trials, we risk introducing ineffective and perhaps unnecessarily harmful treatments into the market, thus sabotaging our fiduciary responsibility on a larger scale. A noninferiority study design comparing an experimental drug to an "established" medication would potentially expose many more participants to ineffective or unsafe treatments than a placebo-controlled study. This dilemma seems to be at the core of the disagreement between regulatory and research funding/ethics agencies.
These opposing views deter us from making a clear statement about the use of a placebo that applies to all situations. Instead, each proposed clinical trial and population must be evaluated individually by research ethics committees to minimize risk to participants, irrespective of whether a placebo is used. For example, including the use of a placebo is not acceptable when there is grave risk of clinical deterioration in severely affected individuals. Some clinical examples include acute suicidality, severe acute psychosis, anorexia nervosa with physical deterioration, and severe psychotic mania.
For conditions or patient subgroups where there is no established or approved psychotropic treatment, the use of a placebo is ethically and scientifically justified and permitted. Some examples include major depressive episodes with mixed features, persistent depressive disorder, treatment-resistant psychosis, paraphilic disorders, and bulimia nervosa.
For conditions where there is an established treatment, trial designs without a placebo, such as active control, treatment as usual, or noninferiority designs, must be considered. A placebo condition can only be considered when there is compelling scientific justification. In some cases, the use of a placebo may be scientifically justified, even when clinical equipoise is not present, by the high placebo response and narrow drug-placebo differences in a particular population (e.g., moderately severe MDD and anxiety disorders) and by the low risk of clinical deterioration.
Whenever a placebo is used in a clinical trial, there must be adequate measures to ensure informed consent, including disclosure of established or available treatments (including nonpharmacological treatments, if applicable), and the potential risks and benefits of experimental and placebo conditions. Additionally, there must not be a risk of serious or irreversible harm from delaying treatment. There should also be clear protocols for dealing with worsening symptoms and severe adverse events.
Conclusions
Ethically, we have fiduciary responsibility to ensure that our patients are treated with effective and safe medications and are not exposed to unnecessary risks when participating in research studies. 
Introduction
De nouveaux médicaments sont nécessaires pour les personnes souffrant de troubles mentaux, et les essais randomisés contrôlés (ERC) par placebo sont encore la méthode la plus employée pour évaluer les nouveaux médicaments. Toutefois, l'utilisation d'un placebo en médecine, particulièrement dans les troubles de santé mentale, demeure un sujet controversé. Un énoncé de principe de 1997 de l'Association des psychiatres du Canada (APC) a résumé les arguments favorables et défavorables à l'utilisation de placebos, et conclu que l'usage du placebo était justifié sur le plan éthique et scientifique, dans certaines conditions 1 . Avec le débat en 
Aspects éthiques
Les principes bioéthiques dictent que l'on ne devrait pas priver les gens de soins de santé efficaces uniquement parce qu'il s'agit de recherche. Ainsi, l'utilisation du placebo en recherche clinique repose sur la notion d'équilibre clinique 5 . L'équilibre clinique renvoie à « une incertitude authentique de la part de la communauté des experts médicaux à l'égard des mérites thérapeutiques comparatifs de chaque volet d'un essai clinique » 6 . Un placebo est donc acceptable seulement lorsqu'il n'y a pas de traitement établi fondé sur des données probantes pour une affection, selon la communauté professionnelle pertinente. Toutefois, quand il existe un traitement établi, un traitement expérimental devrait lui être comparé afin de minimiser les risques pour les participants à la recherche. Une condition préalable aux deux scénarios est que le patient ne sera pas soumis à des risques additionnels ou des dommages sérieux ou irréversibles s'il n'a pas reçu la meilleure intervention éprouvée. 
Position des organismes de financement et de réglementation

Enjeux scientifiques et cliniques
Tout nouveau traitement doit démontrer son efficacité (c.-à-d. comment un traitement fonctionne dans des conditions contrôlées) et son innocuité, avant que l'usage clinique n'en soit approuvé. À l'heure actuelle, comparer un nouveau médicament (ou un autre type de traitement) avec un placebo (ou traitement simulé) à l'aide d'une méthodologie d'ERC est la méthode la plus répandue et la
extrait).
a. Une nouvelle thé rapie ou intervention devrait généralement être évalué e par comparaison avec une autre thérapie efficace éprouvée. b. Comme dans le cas de tous les autres choix de contrôles de rechange, un contrô le par placebo est acceptable sur le plan é thique dans un essai clinique randomisé contrô le seulement si : son utilisation est scientifiquement et mé thodologiquement fiable pour é tablir l'efficacité ou l'innocuité de la thé rapie ou de l'intervention à l'essai; il ne compromet pas la sé curité ou la santé des participants; le chercheur exprime au Comité d'é thique de la recherche (CER) une justification scientifique convaincante de l'usage du contrô le par placebo. c. Pour les essais cliniques utilisant un contrô le par placebo, le chercheur et le CER feront en sorte que les principes géné raux du consentement soient respecté s et que les participants ou leur tiers autorisé soient spé cifiquement informé s : au sujet de toute thé rapie qui sera supprimé e ou suspendue aux fins de la recherche, et des consé quences pré vues de la suppression ou de la suspension de la thé rapie.
plus rigoureuse pour établir l'efficacité et l'innocuité. Les études de non-infériorité 13 , dans lesquelles un nouveau médicament est comparé seulement avec un traitement actif établi, nécessitent généralement des tailles d'échantillon beaucoup plus grandes et n'établissent pas aussi définitivement l'innocuité et la tolérabilité que les études semblables contrôlées par placebo 14, 15 .
Cependant, un placebo n'est pas simplement une substance inerte. Le patient affecté à un placebo bénéficie également des effets thérapeutiques non spécifiques d'un essai clinique, dont l'éducation, les visites régulières, les interactions psychosociales avec le personnel de l'étude, entre autres bénéfices. Ainsi, il n'est pas étonnant que la réponse au placebo soit élevée en psychiatrie et dans d'autres affections chroniques où les symptômes peuvent fluctuer et les résultats sont basés sur l'entrevue avec le patient ou l'auto-déclaration. 
Conclusions
Sur le plan éthique, nous avons la responsabilité fiduciaire de faire en sorte que nos patients soient traités par des médicaments efficaces et sûrs et qu'ils ne soient pas exposés à des risques inutiles quand ils participent à des études de recherche. Les taux de réponse élevée au placebo, la réponse diminuée des médicaments actifs comparés au placebo, et les limitations de la généralisation de l'efficacité font que la pratique clinique « réelle » rend l'évaluation des médicaments psychotropes particulièrement difficile. Dans ce contexte, les contrôles par placebo sont éthiquement justifiés, quand il n'y a pas de traitement établi ou quand il y a une justification scientifique suffisante pour un placebo et que son utilisation n'exposera pas les participants à la recherche à des risques de dommages excessifs. Par conséquent, chaque essai clinique doit être évalué individuellement pour obtenir l'approbation éthique et scientifique de l'usage du placebo.
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